Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Porcupine inhibitors impa… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice

Artikel i vetenskaplig tidskrift
Författare Thomas Funck-Brentano
Karin H. Nilsson
Robert Brommage
Petra Henning
Ulf H Lerner
A. Koskela
J. Tuukkanen
M. Cohen-Solal
Sofia Moverare-Skrtic
Claes Ohlsson
Publicerad i Journal of Endocrinology
Volym 238
Nummer/häfte 1
Sidor 13-23
ISSN 0022-0795
Publiceringsår 2018
Publicerad vid Centre for Bone and Arthritis Research
Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition
Sidor 13-23
Språk en
Länkar dx.doi.org/10.1530/joe-18-0153
Ämnesord Wnt signaling pathway, targeted therapy, osteoporosis, animal models, focal dermal hypoplasia, postmenopausal women, beta-catenin, wnt, cancer, osteoporosis, romosozumab, disease, osteoblasts, progenitor, Endocrinology & Metabolism, ates of america, v109, pe2197, naka h, 1990, international orthopaedics, v14, p179, ates of america, v112, p14972
Ämneskategorier Endokrinologi och diabetes

Sammanfattning

WNT signaling is involved in the tumorigenesis of various cancers and regulates bone homeostasis. Palmitoleoylation of WNTs by Porcupine is required for WNT activity. Porcupine inhibitors are under development for cancer therapy. As the possible side effects of Porcupine inhibitors on bone health are unknown, we determined their effects on bone mass and strength. Twelve-week-old C57BL/6N female mice were treated by the Porcupine inhibitors LGK974 (low dose = 3 mg/kg/day; high dose = 6 mg/kg/day) or Wnt-C59 (10 mg/kg/day) or vehicle for 3 weeks. Bone parameters were assessed by serum biomarkers, dual-energy X-ray absorptiometry, mu CT and histomorphometry. Bone strength was measured by the 3-point bending test. The Porcupine inhibitors were well tolerated demonstrated by normal body weight. Both doses of LGK974 and Wnt-C59 reduced total body bone mineral density compared with vehicle treatment (P < 0.001). Cortical thickness of the femur shaft (P < 0.001) and trabecular bone volume fraction in the vertebral body (P < 0.001) were reduced by treatment with LGK974 or Wnt-C59. Porcupine inhibition reduced bone strength in the tibia (P < 0.05). The cortical bone loss was the result of impaired periosteal bone formation and increased endocortical bone resorption and the trabecular bone loss was caused by reduced trabecular bone formation and increased bone resorption. Porcupine inhibitors exert deleterious effects on bone mass and strength caused by a combination of reduced bone formation and increased bone resorption. We suggest that cancer targeted therapies using Porcupine inhibitors may increase the risk of fractures.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?